MARKET

OCUP

OCUP

Ocuphire Pharma Inc
NASDAQ
3.100
+0.050
+1.64%
Closed 16:00 12/07 EST
OPEN
3.040
PREV CLOSE
3.050
HIGH
3.180
LOW
3.040
VOLUME
64.23K
TURNOVER
113.42K
52 WEEK HIGH
4.430
52 WEEK LOW
1.780
MARKET CAP
64.50M
P/E (TTM)
-2.6367
1D
5D
1M
3M
1Y
5Y
BRIEF-Ocuphire Pharma Announces Submission Of NDA To FDA For Nyxol Eye Drops
Reuters · 1d ago
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
NDA Supported by Positive Phase 3 Data Demonstrating Rapid Reversal of Dilated Eyes and Favorable Safety Profile in Pediatric and Adult SubjectsFARMINGTON HILLS, Mich., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stag...
GlobeNewswire · 1d ago
Ocuphire Pharma Files New Drug Application to FDA for Nyxol to Treat Pharmacologically-Induced Mydriasis
Ocuphire Pharma Files New Drug Application to FDA for Nyxol to Treat Pharmacologically-Induced Mydriasis
MT Newswires · 2d ago
Ocuphire to Present at Five Upcoming Investor/Industry Conferences
FARMINGTON HILLS, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disor...
GlobeNewswire · 11/21 13:00
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Benzinga · 11/09 10:08
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/08 18:41
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 11/08 17:51
Ocuphire Pharma Shares Jump After Global Licensing Pact For Nyxol Eye Drops
Benzinga · 11/08 17:24
More
About OCUP
Ocuphire Pharma, Inc. is an ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its products include Nyxol Eye Drops and APX3330. The Nyxol Eye Drops is a once-daily preservative-free eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol is being developed for several indications, including night vision disturbances, reversal of pharmacologically induced mydriasis and presbyopia. The APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases. Its pre-clinical products are APX2009 and APX2014. APX3330 is in Phase II trial for the treatment of patients with diabetic retinopathy (DR), including moderately severe non-proliferative DR and mild proliferative DR, as well as patients with diabetic macular edema (DME) without loss of central vision.

Webull offers kinds of Ocuphire Pharma Inc stock information, including NASDAQ:OCUP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCUP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCUP stock methods without spending real money on the virtual paper trading platform.